Get the Stockscreener App
1,044.13
0.67%
6.98
After Hours:
1045.82
1.69
+0.16%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,044.13, with a volume of 2.75M.
It is up +0.67% in the last 24 hours and down -3.35% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,037.15
Open:
$1037.57
24h Volume:
2.75M
Relative Volume:
0.79
Market Cap:
$934.52B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
51.64
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
-1.75%
1M Performance:
-3.35%
6M Performance:
+36.97%
1Y Performance:
+28.73%
1-Day Range:
$1,037.57
$1,057.41
1-Week Range:
$1,004.14
$1,073.39
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,044.13 | 928.27B | 59.42B | 18.41B | 6.44B | 20.22 |
|
AZN
Astrazeneca Plc
|
188.41 | 287.64B | 58.07B | 9.40B | 9.87B | 3.0115 |
|
JNJ
Johnson Johnson
|
230.75 | 547.51B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
225.64 | 394.14B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
151.04 | 285.29B | 54.45B | 14.42B | 17.15B | 7.333 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
FDA Moves To Bring Pharma Manufacturing Back To US With New Pilot - Benzinga
Eli Lilly chooses rural Pennsylvania for $3.5B weight-loss drug production - Manufacturing Dive
UBS reiterates Buy rating on Eli Lilly stock ahead of competitor study - Investing.com
Eli Lilly CEO Says Medicare Coverage Of Obesity Drugs Could Be Game-Changer For Its Weight-Loss Pill - AOL.com
Should Investors Buy, Sell or Hold Lilly Stock Ahead of Q4 Earnings? - Finviz
Eli Lilly to Open $3.5B Manufacturing Facility in Pennsylvania’s Lehigh Valley - REBusinessOnline
Eli Lilly selects Pennsylvania for $3.5bn obesity drugs manufacturing site - Pharmaceutical Technology
Eli Lilly and Company (LLY) Forms Strategic Collaboration with Repertoire Immune Medicines - Insider Monkey
3 Headwinds Facing Pfizer in 2026 - The Motley Fool
Eli Lilly Plans $3.5 Billion Pennsylvania Plant for New Obesity Drug - AIM Media House
Gimbal Financial Has $10.75 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Acquired by Guerra Advisors Inc - MarketBeat
Obesity market sales potential tightens as Novo and Lilly enter new era - Reuters
Atlantic Union Bankshares Corp Has $29.42 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
UBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,250 - 富途牛牛
Eli Lilly and Company $LLY Shares Acquired by Nicholson Wealth Management Group LLC - MarketBeat
Eli Lilly and Company $LLY Shares Purchased by Jones Financial Companies Lllp - MarketBeat
Strategy Asset Managers LLC Has $14.14 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Sold by AGF Management Ltd. - MarketBeat
Arjuna Capital Purchases 3,886 Shares of Eli Lilly and Company $LLY - MarketBeat
30 trillion to 50 trillion won. This is the annual sales estimate of Eli Lilly and Novo Nordisk last.. - 매일경제
News | Lilly manufacturing investment extends biotech trend; Tariffs drive up building material costs; Record Valentine's spending expected - CoStar
ICYMI: Eli Lilly’s $3.5B Lehigh Valley Plant Deal Promises 850 Jobs - MyChesCo
National Mutual Insurance Federation of Agricultural Cooperatives Sells 5,500 Shares of Eli Lilly and Company $LLY - MarketBeat
Meridian Wealth Management LLC Buys 1,035 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Acquired by Donaldson Capital Management LLC - MarketBeat
Principal Financial Group Inc. Acquires 11,954 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Acquired by Mediolanum International Funds Ltd - MarketBeat
Thrivent Financial for Lutherans Acquires 5,787 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company (LLY) Earns Fresh Bullish Calls from Analysts - Finviz
Historic $3.5 Billion Eli Lilly Bet Promises 850 Jobs in Lehigh Valley - MyChesCo
Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch - TechStock²
Eli Lilly Commits Billions to Expand Production for Weight-Loss Drugs - AD HOC NEWS
Eli Lilly and Company (LLY) Expands U.S. Manufacturing and Advances Breakthrough Therapies - Insider Monkey
Eli Lilly (LLY) Taps Gene-Editing Technology to Target Hearing Loss, Reuters Reports - Finviz
Eli Lilly Expands Beyond GLP-1 With New Facility And Alliances - simplywall.st
Eli Lilly and Company $LLY Shares Purchased by Cornerstone Wealth Management LLC - MarketBeat
Welch & Forbes LLC Boosts Position in Eli Lilly and Company $LLY - MarketBeat
National Pension Service Has $1.21 Billion Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Holdings Lessened by L.M. Kohn & Company - MarketBeat
Eli Lilly and Company (NYSE:LLY) Cut to Buy at Wall Street Zen - MarketBeat
Lilly to build $3.5 billion manufacturing facility in Lehigh Valley By Investing.com - Investing.com Nigeria
Eli Lilly to build $3.5 billion Pa. plant, create 850 jobs - PennLive.com
Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as traders eye Feb. 4 results - TechStock²
Eli Lilly Plots $3.5B Manufacturing Facility In Lehigh Valley - Bisnow
Ticker: Eli Lilly announces new plant in Pennsylvania; AmEx profits surge 13% - Boston Herald
How the Lehigh Valley landed a ‘generational’ pharmaceutical plant - lehighvalleylive
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Eli Lilly to build $3.5B plant in Pennsylvania's Lehigh Valley to produce weight-loss drugs - CBS News
Eli Lilly Fails to Win EU Approval for Mounjaro Heart Failure La - GuruFocus
Eli Lilly to build $3.5 billion Lehigh Valley complex, company’s first Pa. plant - The Morning Call
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
103.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):